mortality/aging
• increased time of tumor free survival following treatment with medroxyprogesterone acetate (MPA) and 7, 12-dimethylbenzanthracene (DMBA)
|
neoplasm
• decreased mammary tumor incidence following treatment with medroxyprogesterone acetate (MPA) and 7, 12-dimethylbenzanthracene (DMBA)
|
endocrine/exocrine glands
• transient delay in ductal outgrowth from 3 to 5 weeks of age
• however, no significant differences are detected at later time points or during pregnancy and lactation
|
reproductive system
N |
• fertile
|
homeostasis/metabolism
• increased time of tumor free survival following treatment with medroxyprogesterone acetate (MPA) and 7, 12-dimethylbenzanthracene (DMBA)
|
• decreased mammary tumor incidence following treatment with medroxyprogesterone acetate (MPA) and 7, 12-dimethylbenzanthracene (DMBA)
|
integument
• transient delay in ductal outgrowth from 3 to 5 weeks of age
• however, no significant differences are detected at later time points or during pregnancy and lactation
|